Clinical outcomes in patients with node-negative breast cancer treated based on the recurrence score results: evidence from a large prospectively designed registry
Salomon M. Stemmer(Tel Aviv University), Nicky Liebermann(Clalit Health Services), Tara Maddala, Debbie McCullough(Genomic Health (United States)), Georgeta Fried(Roche (Switzerland)), Noa Ben-Baruch(Kaplan Medical Center), Lior Soussan‐Gutman(Teva Pharmaceuticals (Israel)), Steven Shak(Genomic Health (United States)), Shulamith Rizel(Rabin Medical Center), Bella Kaufman(NYU Langone Health), Avital Bareket‐Samish, David Geffen(Ben-Gurion University of the Negev), Beatrice Uziely(Hadassah Medical Center), Ella Evron(Sidney Kimmel Comprehensive Cancer Center), Christer Svedman(Genomic Health (United States)), Kevin Isaacs(Emek Medical Center), Hadassah Goldberg(Bar-Ilan University), Mariana Steiner(Sheba Medical Center), Bella Nisenbaum(Meir Medical Center), Shmuel Klang(Hebrew University of Jerusalem), Natalya Karminsky(Wolfson Medical Center), Larisa Ryvo(Tel Aviv Sourasky Medical Center), Jamal Zidan(Rebecca Sieff Hospital), Ora Rosengarten(Sheba Medical Center)
Cited by 70
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)
|Annals of Oncology|2020|1.4k
4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)
|Annals of Oncology|2018|1.2k